Five Prime Therapeutics, Inc.
11 clinical trials · Sponsor
◉ Watch Five Prime Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| FPT155 in Patients With Advanced Solid Tumors (NCT04074759) | Five Prime Therapeutics, Inc. | 2018-10-18 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (NCT03694522) | Five Prime Therapeutics, Inc. | 2018-09-14 |
| FPA150 in Patients With Advanced Solid Tumors (NCT03514121) | Five Prime Therapeutics, Inc. | 2018-03-27 |
| A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (NCT03343301) | Five Prime Therapeutics, Inc. | 2017-11-30 |
Track Five Prime Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.